Bozitinib is named as an intervention in 2 current clinical trials in our UK, USA and China registers. 2 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Apollomics Inc (1). The most-studied condition is Solid Tumors.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT03175224 · Solid Tumors, Advanced Cancer, Renal Cancer
|
Phase 2 | Recruiting | Apollomics Inc. | UK, USA |
|
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
NCT06343064 · ClinicalTrials.gov ↗ · Non-Small-Cell Lung Cancer
|
Phase 1/2 | Recruiting | Avistone Biotechnology Co., Ltd. | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Apollomics Inc. | 1 |
| Avistone Biotechnology Co., Ltd. | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in UK | 1 | 1 |
| Clinical trials in USA | 1 | 1 |
| Clinical trials in China | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our UK, USA and China registers name Bozitinib (also registered as APL-101) as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 1 with sites in UK, 1 with sites in USA and 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Apollomics Inc (1) and Avistone Biotechnology Co., Ltd (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Bozitinib works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Bozitinib works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Bozitinib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.